CLDF Title
Home | Contact Us | Bookmark
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information: Cirrhosis, cancer risks higher with NAFLD- especially in diabetics

Cirrhosis, cancer risks higher with NAFLD- especially in diabetics

Last Updated: 2019-05-27

By Will Boggs MD

(Reuters Health) - The increased risk of cirrhosis and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease (NAFLD) is particularly marked in people with diabetes, according to a large study from Europe.

"We probably need a more systematic way of detecting the liver disease in patients at risk so we can prevent progression," Dr. William Alazawi from Barts Liver Center and the University of London told Reuters Health by email. "This involves raising awareness of liver disease among patients and their doctors and also making the most of the blood tests and scans that currently exist in people who we know are at risk."

Dr. Alazawi's team studied data on 18 million Europeans, to investigate the odds that people with NAFLD or non-alcoholic steatohepatitis (NASH) would develop cirrhosis or liver cancer.

After accounting for age, smoking, and body mass index, the researchers found people with NAFLD or NASH were almost five times more likely than people with healthy livers to develop cirrhosis and 3.5 times more likely to develop liver cancer.

Compared to people with NAFLD or NASH and mild liver fibrosis, those with high-risk liver fibrosis were more than 33 times more likely to develop cirrhosis and 25 times more likely to progress to cancer, according to the May 20th BMC Medicine online report.

Among people with NAFLD or NASH, those with diabetes were more than twice as likely as those without diabetes to develop liver cirrhosis or cancer.

Overall, about half of the patients who developed cirrhosis did so within two or three years after their NAFLD was first diagnosed and within as little as six months after a diagnosis of NASH.

"The fact that patients acquired a diagnosis of cirrhosis or HCC within a few years of being diagnosed with NAFLD/NASH (suggests) that patients are being diagnosed late in the disease course," Alazawi said.

"Knowing that diabetes is an independent predictor of cirrhosis and liver cancer is very important from a clinical point of view, as it helps us focus efforts to find patients who may benefit from intervention," Alazawi said.

"Liver disease can progress 'silently' to advanced stages," he said, "and people with diabetes are at increased risk. This reminds doctors to consider assessing the liver as they review people with diabetes and also encourages patients to look at lifestyle, losing weight, and cutting back the amount (of alcohol) they drink."


BMC Medicine 2019.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2019 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.